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SUMMARY 
 
 Due to the biological importance of heme and its implication in various disease 
states, uncovering how it is transported throughout the cell is of vital importance. Some 
of the strongest in vivo tools present in the literature are FRET-based sensors using a 
number of chromophores that are optimized and expanded from GFP. In order to 
elucidate the movement of heme throughout the cell, GFP FRET-based heme sensors 
were designed, expressed, and purified to be further characterized in vitro. This series of 
heme sensors were expressed in Saccharomyces cerevisiae to monitor the in vivo 
movement of heme. Different growth conditions were explored to monitor the effect of 
these changes to cytosolic heme availability. These heme sensors are now poised to 
address the movement of heme from the mitochondria to other targets in the cell under a 
variety of conditions. This will provide insight into heme trafficking pathways, as well as 














1.1 Heme Biology 
Heme is an essential but cytotoxic iron-containing protein cofactor and signaling 
molecule. While its biosynthesis and degradation are well understood, little is known 
about the transport and trafficking of heme. Knowledge of the latter will have a 
tremendous impact on understanding how cells assimilate heme into metabolism while 
also mitigating its inherent cytotoxicity. Our approach toward studying heme homeostasis 
is to couple intracellular heme imaging with genetic screens to identify genes that, when 
overexpressed or deleted, will alter the distribution of heme. Towards this end, we 
describe the design and characterization of the first genetically encoded ratiometric heme 
sensors, which will be used in future studies to study heme trafficking and signaling. 
 Heme is an iron-containing porphyrin that can adopt several different oxidation 
states and take on a variety of structures. The most biologically abundant variant of heme, 
heme b, is used as a cofactor for a wide range of proteins, including peroxidases,1 and 
contains two vinyl, two propionate, and four methyl side chains. The coordinated iron 
atom within the porphyrin ring can either adopt a ferric (Fe3+) or ferrous (Fe2+) oxidation 
state. The other common variants of heme, heme a and heme c, are used as cofactors for 
the enzyme cytochrome c oxidase2 and as a covalently attached cofactor in c-type 
hemoproteins3, respectively.  
 Heme is synthesized in the mitochondria through a highly conserved eight-step 
process known as the Shemin pathway.4 This process begins with the condensation of 
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glycine and succinyl-coenzyme A (succinyl-CoA) to give the first intermediate δ-
aminolevulinic acid (ALA) and ends with Fe2+ insertion into protoporphyrin IX to 
produce heme (iron protoporphyrin IX). Heme is then redistributed to multiple organelles 
in a number of locations across the cell including the mitochondrial intermembrane 
space, cytosol, endoplasmic reticulum (ER), and nucleus to perform its numerous 
functions.  
 
1.2 Functions of Heme 
 Cellular functions of heme include chemical catalysis5, electron transfer6, gas 
binding and transport7, and involvement in various signaling pathways8. Recently, it has 
been found that heme catalyzes an increase in peroxidase activity and the reduction 
potentials increase in the relevant redox intermediates when heme covalently binds to a 
heme peroxidase1. Heme is utilized as a prosthetic group in cytochrome c, and facilitates 
electron transfer between Complex III and Complex IV in the electron transport chain3. 
Due to the high reactivity of the iron center in heme, cytochrome c is shown to fully 
envelop its substrate in order to efficiently and selectively transport electrons and to 
avoid adverse redox reactions9. The demand for molecular oxygen in various roles 
throughout biology necessitates its transport through the organism at the cellular level, as 
well as at the systems level. Two of the most studied oxygen binding and transport 
molecules, myoglobin (Mb) and hemoglobin (Hb), utilize heme as their prosthetic group 
allowing for the binding and transport of oxygen in muscle tissues and blood, 
respectively.10 Heme is also implicated in a number of sensing pathways including 
cellular oxygen sensing through activation of the transcription factor Neuronal PAS 
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domain 2 (NPAS2) when heme is bound to the PAS domain.7 As an effector molecule, 
heme is found to regulate gene expression in yeast.11  
 As seen above, heme performs various functions in every cellular compartment 
including chemical catalysis of peroxidases in the endoplasmic reticulum peroxidases, 
acting as a cofactor across complexes in the respiratory pathway in the mitochondria, and 
in the activation of transcription factors in the nucleus. Its transport to these different 
compartments is largely unknown, calling for a reliable method to visualize the 
movement of heme in vivo.  
 
1.3 Cytotoxic Effects of Free Heme  
Despite its essentiality, heme is cytotoxic due to its ability to induce oxidative 
stress12 and to interact with membranes13. Indeed, free heme can aid in the production of 
reactive oxygen species (ROS). ROS are highly reactive in the cellular environment and 
include the compounds superoxide anion (O2-) and hydroxyl radical (OH). These ROS 
have been implicated in the damage of DNA, lipids, and proteins.12 Heme is lipophilic 
and, when its biosynthesis, trafficking, and degradation is misregulated, can lead to heme 
aggregation at the membrane resulting in oxidation, leading to an increase in permeability 
and a variety of membrane disorders.13  
A number of pathologies including Alzheimer’s Disease (AD), Parkinson’s 
Disease (PD), and Huntington’s Disease (HD) have been shown to have a misregulation 
of heme that leads to, or happens concurrently with, their disease state12. AD is the most 
common age-related neurodegenerative disease that is characterized by the accumulation 
of insoluble extracellular amyloid-β protein (Aβ) plaques in the synaptic gap, as well as 
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the formation of neurofibrillary tangles (NFTs) in neurons – caused by the aggregation of 
hyperphosphorylated Tau protein.14 Heme and copper (Cu) have been found to bind Aβ 
peptides together, as seen in Figure 1, and produce a large number of partially-reduced 
oxygen species (PROS) like H2O2, implying the potential for heme-Cu-Aβ complexes to 
contribute toxicity to the AD pathology.15 When heme is mistrafficked there is an 




Figure 1. Heme-Cu complex that binds the Aβ peptide in Alzheimer’s Disease. The iron 
center can catalyze the production of toxic H2O2. This figure was taken from Pramanik et 
al. (2011) as Abstract Figure.15 
 
 
neurodegenerative disorder that is characterized by the loss of dopaminergic neurons in 
the substantia nigra and the deposition of intracellular Lewy bodies.12 While there is not 
a clear picture of how or when this happens, iron levels are shown to be increased in the 
substantia nigra which could lead to the production of ROS and lipid peroxidation.12 
Since heme is a cellular source of iron upon its degradation, its premature degradation 
could lead to the increase in iron shown in the PD pathology. The same is true in the HD 
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pathology, which shows increased iron levels during the early stage and a continued 
increase in iron levels as the disease progresses12. This could be indicative that iron plays 




Figure 2. Current model proposed for heme transport throughout the cell. Heme (red 
cross) is synthesized in the mitochondria but the possible pathways it takes to reach all 
cellular targets like the rough endoplasmic reticulum (RER) are unknown (illustrated 
with black arrows and question marks)3. This figure was taken from Severance and 
Hamza (2009), as Figure 2. 
  
 
Recognizing that heme is biosynthesized in the mitochondria, that heme performs 
diverse roles previously discussed in almost all organelles of the cell, and that free heme 
has been shown to be incredibly cytotoxic, it would stand to reason that there is a well-
developed system to closely regulate the trafficking of heme from the mitochondria to its 
various targets to avoid adverse effects. As illustrated in Figure 2, heme is used in almost 
all organelles of the cell. There are two main hypotheses as to how heme is transported to 
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perform its numerous functions across the cell.3 The first is a chaperone independent 
process in which the presence of a labile heme (shown by the red cross) pool in the 
cytosol that can be activated in response to a stimulus and then shuttled to different 
organelles3. The second hypothesis is a chaperone dependent process where heme is more 
tightly regulated and transported to its destinations by heme chaperones upon production 
in the mitochondria3. This hypothesis is largely favored due to the catastrophic effects 
labile heme can have in the cell. Currently, the means by which heme is transported 
throughout the cell is largely unknown, calling for a way to visualize heme in order to 
better understand heme biology and how its misregulation may play a role in a number of 
pathologies. 
 
1.4 Current Methods of Heme Detection 
 Currently, there are no methods that can image labile heme and how it moves 
throughout intact cells. Heme exhibits rich electronic and vibrational spectra that can be 
used to find its concentration and coordination environments. These properties are largely 
utilized in techniques such as Ultraviolet-visible (UV-Vis) spectroscopy, Resonance 
Raman, and photothermal microspectroscopy. UV-Vis spectroscopy measures the 
characteristic absorption of heme and can yield concentrations, coordination states, and 
other electronic properties. This method falls short in its relative insensitivity when 
compared to other methods such as fluorescence spectroscopy. Resonance Raman 
spectroscopy utilizes a laser that excites a molecule within its electronic absorbance band 
to produce large Raman enhancements for the vibrational modes of the molecule16. This 
method can visualize structural changes in heme that can be related to oxygen binding 
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and transport in the hemoproteins Mb and Hb, as well as electron transfer along the 
electron transport chain16. While Raman microscopy is able to spatially resolve heme 
pools, it largely reports on the most abundant hemoproteins, which have inert populations 
of heme, thus still leaving us unable to visualize the movement of labile heme. 
Photothermal microspectroscopy is derived from two parent techniques, infrared (IR) 
spectroscopy and scanning thermal microscopy (SThM). Photothermal 
microspectroscopy is able to spatially resolve spectroscopic properties to a scale of about 
20-30 nm. This technique is very useful in determining which oxidation state heme is in 
when it’s used as a cofactor for various enzymes and macromolecules, but still falls short 
in its ability to monitor labile heme pools in intact cells17.  
 In an effort to increase sensitivity, fluorescent heme analogs have been 
implemented as tracers to monitor heme transport in intact cells18. While the sensitivity 
and ability to visualize heme movement is largely improved in this method, the major 
drawback is that these analogs are chemically different from heme and can dramatically 
alter the fundamental coordination chemistry of the metalloporphyrin. This becomes an 
issue in trying to elucidate various heme transport and trafficking pathways because these 
variants can give rise to their own distinct trafficking and transport schemes, skewing the 
visualization of the natural pathways heme takes throughout the cell. Due to the 
drawbacks of the aforementioned methods, a new method must be devised in order to 
monitor natural heme movement in cells without perturbing the endogenous pathways to 
gain a clear understanding of how heme is transported throughout cells. If successful, this 
method could be paired with other methods, like genetic screens, to fully uncover the 
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heme biology of different organisms and to better understand what effects, if any, heme is 
having in the progression of several disease states.  
The development of fluorescent reporters for transition metals has greatly aided in 
understanding the functions of metals in biology. Small molecule fluorescent probes have 
been developed and used in vivo to report on the level of the target transition metal, but 
they struggle with toxicity and solubility19,20. Many small molecule fluorescent sensors 
also have difficulty reaching a high enough affinity to monitor transition metal levels in 
extremely low concentrations in a cellular environment21. To resolve this issue, 
genetically encoded fluorescent protein-based sensors have been developed. Green 
Fluorescent Protein (GFP) was isolated from the jellyfish Aequorea victoria in 196122 
and further optimized to gain increased brightness as well as expand the library of colors 
emitted to increase use in cells23. One of the major benefits of using fluorescent proteins 
(FPs) is the ability to control their localization, as well as pairing them with other FPs for 
ratiometric imaging via Förster Resonance Energy Transfer (FRET).24 FRET has been 
utilized to sense multiple analytes, including metals like zinc and copper. For example, 
Dittmer et al. (2009) used these FRET sensors to visualize the subcellular localization of 
zinc in living cells. They utilized a zinc-binding domain that resulted in a conformational 
change upon zinc binding, bringing the two chromophores close enough for FRET to 
occur25. These FRET sensors were then further developed to simultaneously monitor zinc 
uptake into different subcellular compartments. To accomplish this, two FRET pairs, 
green-red and cyan-yellow, were used concurrently to monitor zinc uptake in different 
compartments including the nucleus, ER, Golgi, and mitochondria26. As seen in Figure 3, 
these two FRET pairs were imaged while being colocalized in the same set of cells.   
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Figure 3. Colocalization of two FRET pairs. The Cyan-Yellow FRET pair was targeted 
to the yeast cytosol (left panel) to show cytosolic zinc concentrations. The Green-Red 
FRET pair was targeted to the yeast nucleus (middle panel) to show nuclear zinc 
concentrations. The overlay of these two images shows their utility within the same cells 
simultaneously. This figure was taken from Miranda et al. (2012), as Figure 4c.26 
 
 
These powerful tools can be used to monitor the movement of metals and small 
molecules in living cells under a multitude of conditions. The strength of FRET lies in the 
ability to design sensors with high specificity for different ligands, subcellular targeting, 
and the plethora of FPs that have been created to cover the entire visible range, into near-
IR and near-UV as well.  
 Due to the success of previous FRET-based sensors for the in vivo monitoring of 
various analytes, the same approach toward the study of heme will significantly aid in 
better understanding its cell biology, including its transport, trafficking, and role in 
signaling. Herein, I report the design, purification, and initial in vivo characterization of a 
novel heme-dependent ratiometric FRET sensor.  
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CHAPTER 2 
DESIGN AND PURIFICATION OF HEME SENSORS 
 
2.1 Introduction  
 Our heme-dependent FRET sensor, Heme Sensor 1 (HS1), was designed as a 
tridomain sensor including a heme-dependent FRET donor, eGFP, that is fused to the 
heme-binding region cytochrome b562 (cyt b562)27, which acts as the FRET acceptor, and a 




Figure 4. HS1 ribbon model depicting the FRET donor, eGFP, cyt b562, which binds the 
FRET acceptor, heme, and the heme- and eGFP-insensitive chromophore, mKATE227.  
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FRET is an extremely useful tool that takes advantage of the dipole-dipole interactions 
resulting from overlap between the excited state of one chromophore (donor) and the 
ground state of another chromophore (acceptor). The efficiency of FRET is highly 
dependent upon distance between and orientation of two chromophores28. These qualities 
make FRET pairs very useful in monitoring a ligand binding event if a conformational 
change takes place upon binding, bringing the donor and acceptor closer together, 
resulting in a change in fluorescence. FRET is sensitive to changes with the relation 1/r6 
with r being the distance between chromophores28. The acceptor molecule, heme, can 
accept the excited-state energy from the donor molecule, eGFP, when they are brought in 
close proximity to each other. To accomplish this, the heme binding domain cyt b562 was 
fused to eGFP, bringing the heme close enough to eGFP for FRET to occur. Cyt b562 is an 
Escherichia coli (E. coli) electron transport protein that binds heme using a His/Met 
coordination, Met7 and His102.29,30 
While heme does not fluoresce, it can accept energy between 400-600 nm, which 
overlaps with the fluorescence emission of eGFP between 510-530 nm. Due to this 
overlap, if heme can be positioned near the eGFP chromophore, it will accept the excited 
state energy from eGFP, thereby quenching fluorescence. In order to maximize this 
effect, Arpino et al. (2012) tested the insertion of cyt b562 into eGFP to optimize the 
quenching of eGFP fluorescence upon heme binding27. This was accomplished by 
utilizing the nonhomologous recombination method, transposon mutagenesis, which 
involves creating a library in which cyt b562 was randomly inserted into eGFP, and then 
screened for mutants that retained full eGFP fluorescence. The mutants that did exhibit 
undisturbed fluorescence after cyt b562 insertion were then sequenced, and mutants that 
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showed correct sequences were screened for their ability to be fully quenched upon heme 
binding. Three mutants were chosen that retained full excitation of eGFP at 488 nm and 
were fully quenched by heme binding. These mutants, CG2, CG4, and CG6, were found 
to all be quenched to the same degree upon heme binding, but CG6 had behavior 
mirroring that of native cyt b562 in that it had a similar KD value for heme. CG2 and CG4 
were found to require 7.5- and 3-fold greater concentration of heme, respectively, in 
order to achieve full quenching of the eGFP chromophore. For this reason, CG6 was 
obtained from Arpino et al. (2012) and was chosen as the ideal two-domain scaffold on 
which to build our sensor.  
To be confident that the fluorescence quenching observed is due to heme binding, 
and not an indirect event that is modifying or denaturing the chromophore, an internal 
standard that accounts for inherent fluctuations in fluorescence is necessary. To address 
this, we fused another chromophore, mKATE2, to CG6 via a Gly-Ser linker. mKATE2 
(excitation: 588 nm, emission: 633 nm) is largely insensitive to energy transfer from 
eGFP (excitation: 488 nm, emission: 510 nm) and heme31. This chromophore is 
beneficial as an internal standard because its fluorescence will not change in the presence 
of heme, but it will indicate if the cellular environment is prematurely degrading the 
chromophores. By utilizing CG6 and mKATE2, we have designed a ratiometric heme 
sensor that will change with varying concentrations of heme. The fluorescence ratio of 
eGFP to mKATE2 will change as heme availability fluctuates. An increase in heme 
binding will result in a decrease in eGFP fluorescence and no change to the mKATE 
fluorescence emission, thus lowering the eGFP:mKATE2 fluorescence ratio. 
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To purify HS1, a number of methods were tested until pure protein was isolated. 
The first step was to fuse a hexahistidine tag (his6-tag) to the N-terminus of the protein. 
We utilized the his6-tagged HS1 on a nickel affinity column (Ni column) to separate HS1 
from other proteins present in the crude lysate. Due to histidine’s ability to bind heme, it 
was then imperative to remove the his6-tag from HS1 so that it would not skew binding 
affinities and heme concentrations32. To do this, a thrombin site was added to allow 
selective cleavage of the his6-tag from HS1. The use of thrombin proved difficult due to 
precipitation of HS1 upon cleavage attempts. To overcome this, a TEV protease cleavage 
site was then added to HS1 between the his6-tag and the N-terminus of mKATE2. TEV, a 
cysteine protease, has been shown to be highly selective and widely used in protein 
purification for the cleavage of his6-tags33. The TEV that was used in this purification 
also had a his6-tag engineered onto it so that following cleavage, the his6-tag from HS1, 




Figure 5. Linear, cartoon design of HS1 including the his6-tag and the TEV cleavage site 
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2.2 Purification of HS1 
Purification of this protein began with cloning CG6 into pET30a(+), which 
already had a his6-tag at the N-terminus, via BamHI and HindIII restriction sites. 
mKATE2 was then fused to the N-terminus of CG6 via a BamHI restriction site linker, 
for expression in E. coli BL21(DE3). Initially, the success of the TEV digest was unclear 
due to the relatively small change in molecular weight before and after cleavage of the 
his6-tag (0.82 kDa), unable to be reliably resolved by Sodium Dodecyl Sulfate 
Polyacrylamide Gel Electrophoresis (SDS-PAGE). For this reason, Maltose-Binding 
Protein (MBP) was fused to the N-terminus of mKATE2. As MBP is a 42.5 kDa protein, 
it adds the mass necessary to visualize TEV cleavage by SDS-PAGE34. This modification 
was highly useful in determining the efficiency of the his6-TEV protease, but created 
more problems in the purification route. After the addition of MBP, the expression of 
HS1 fluorescence was adversely affected, resulting in an overall loss in protein color, a 
decrease in chromophore absorbance and fluorescence, and a loss in efficient separations 
on the Ni column. This modification was discarded due to the problems it created, but 
was useful in initially detecting the cleavage efficacy of the modified his6-TEV protease.  
We returned to the original design of HS1, sans MBP, and continued on with the 
purification route. Upon cell lysis, the cell-free extract was applied to a Ni column was 
run to separate his6-HS1 from other proteins present in the cell lysate. Imidazole was 
used to selectively outcompete the his6-tag on the Ni column upon an increase in 
imidazole concentration. After elution of HS1, as seen visually by the pink color of the 
protein, SDS-PAGE was performed to confirm the relative purity of HS1 compared to 
that of the crude lysate. As seen in Figure 6, the crude lysate showed a multitude of 
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proteins that largely eluted in the flow through (FT), indicating a lack of interaction with 




Figure 6. SDS-PAGE confirming efficiency of Ni column for HS1 (65 kDa) purification. 
Lane 1: HS1 crude lysate. Lanes 2-4: HS1 flow through in low imidazole wash. Lanes 5-
11: HS1 elution from various minutes (min) throughout the gradient elution. Lane 12: 
molecular weight ladder.  
 
 
The other wells on the gel show samples from 79.5 minutes to 91.5 minutes, during the 
gradient increase in elution buffer. At 65 kDa, HS1 runs close to the 71 kDa marker. It 
was consistently seen to run slightly above the molecular weight marker but the band was 
confirmed as HS1 via MALDI-MS. The HS1 was also found to run in a duplicate state, as 
indicated by the presence of two bands close together, which could be due to two 
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was confirmed by running a sample of relative purity on the HPLC and seeing only one 
peak where HS1 eluted. In order to better understand and confirm this phenomenon, 
samples could be differentially denatured to see if the population of the two bands 
increase or decrease. Three samples, 79.5 min, 81.5 min, and 83.5 min were combined 
and dialyzed against TEV cleavage buffer to remove imidazole.  
 After dialysis was complete, the his6-HS1 sample was digested with TEV to 
cleave the his6-tag. A sample of HS1 without TEV was also left at room temperature with 
the TEV cut sample in order to have a control to run on the Ni column that had not been 
exposed to TEV. The HS1+TEV sample was run on the Ni column and HS1 eluted in the 
flow through, as indicated by the elution of the pink-colored protein. Once the column 
was re-equilibrated in equilibration buffer (10 mM Tris, 100 mM NaCl, pH 8, 20 mM 
imidazole), the HS1+buffer control was run on the Ni column and HS1 was shown to 
stick to the column until it was eluted with elution buffer (10 mM Tris, 100 mM NaCl, 
pH 8, 300 mM imidazole), confirming the presence of an intact his6-HS1. In order to 
confirm the purity of HS1, and the lack of the TEV protease, SDS-PAGE was performed 
with various samples after elution of the HS1+TEV sample. As seen in Figure 7, a large  
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Figure 7. SDS-PAGE after TEV digest and Ni column to obtain HS1 (65 kDa) without 
the his6-tag. Lanes 1-2: HS1+TEV before running on Ni column. Lanes 3-11: HS1 
elution from various minutes (min) throughout the low imidazole elution. Lane 12: 
molecular weight marker. 
 
 
amount of impurities were shown to co-elute with HS1. However, the TEV protease was 
largely removed from the samples due to the his6-TEV interacting with the Ni column. In 
order to obtain pure HS1, ion exchange chromatography was performed to selectively 
elute HS1. With a calculated isoelectric point (pI) of 6.59, a cationic column was utilized 
to selectively isolate HS1 based on size and amino acid content. To increase the 
likelihood of finding pure samples, smaller fractions were collected and checked via 
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Figure 8. SDS-PAGE confirming HS1 (65 kDa) purity after ion exchange 
chromatography. Lane 1: HS1 sample before ion exchange chromatography. Lanes 2-7: 
empty wells. Lanes 8-11: HS1 elution from various minutes (min) throughout the 
gradient elution. Lane 12: molecular weight ladder. 
 
 
All of the HS1 samples that demonstrated protein purity were combined, 
concentrated via spin concentration, and were stored at 4 °C to be used in further 
experiments. 
 
2.3 Creating a Library of HS1 Mutants 
Since HS1 was typically 95% bound with heme, a different sensor was needed to 
better monitor changes in heme concentrations. It is important to create a sensor that is 
neither over-saturated or under-saturated so that the sensor can reliably monitor both 
































	   	   	  19	  
would bind heme with a different affinity, a cyt b562 Met7Ala mutation was prepared. We 
hypothesized this mutant to give a weaker binding sensor due to the disruption of the 
coordination environment. HS1 was shown to be fully quenched in wild type (WT) cells, 
so it would not be a good tool to monitor an increase of heme. For this reason, HS1-
monoHis was cloned and purified.  
Following very closely with the HS1 purification, HS1-monoHis was transformed 
into the expression strain E. coli BL21(DE3) to overexpress the mutant proteins. After 
cell lysis, the 20 mL Ni column was then used to purify the crude HS1-monoHis, and the 
fractions found to contain the protein were dialyzed to remove imidazole. As seen in 
Figure 9, HS1-monoHis eluted with the presence of several impurities, but most of the 
other proteins shown in the crude lysate came out in the flow through. 
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Figure 9. SDS-PAGE confirming efficiency of Ni column for HS1-monoHis (65 kDa) 
purification. Lane 1: HS1-monoHis crude lysate. Lane 2: HS1-monoHis flow through in 
low imidazole wash. Lanes 3-9: HS1-monoHis elution from various minutes (min) 
throughout the gradient elution. Lane 10: molecular weight ladder. 
 
 
Samples 73 min, 75 min, and 77 min were combined and dialyzed to remove imidazole. 
Following dialysis, a digest was performed using a 1:1 molar ratio of HS1-monoHis:TEV 
over 18 hours. A second nickel affinity column was run to separate the HS1-monoHis 
from the his6-tag and TEV protease. This protein also showed other impurities present 
after the second Ni column, necessitating a run on the ion exchange column. After 
fractions were collected from the ion exchange column, they were checked via SDS-
PAGE for purity. As seen in Figure 10, HS1-monoHis was successfully purified and 
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Figure 10. SDS-PAGE confirming HS1-monoHis (65 kDa) purity after ion exchange 
chromatography. Lane 1: molecular weight ladder. Lane 2: HS1 sample before ion 
exchange chromatography. Lanes 3-12: HS1 elution from various minutes (min) 
throughout the gradient elution.  
 
 
To account for the possibilities of heme non-specifically binding to either 
chromophore, a mutant of HS1 was made that had the heme-binding region, cyt b562, 
removed, creating an mKATE2-eGFP Fusion protein. The purification of this control 
differs in its protease cleavage site from the two previous samples in that it retained a 
thrombin site instead of a TEV site. This was due to success in earlier purification of an 
eGFP clone using thrombin and the ease of cloning mKATE2 into that existing clone. 
The Fusion plasmid was transformed into E. coli BL21(DE3). After cell lysis, the 20 mL 
Ni column was then used to purify the crude Fusion and the fractions found to contain the 
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eluted with the presence of several impurities, but most of the proteins shown in the crude 
lysate came out in the flow through. Samples 70 min, 72 min, 74 min, 76 min, and 78 




Figure 11. SDS-PAGE confirming efficiency of Ni column for mKATE-eGFP fusion 
(53.25 kDa) purification. Lane 1: mKATE2-eGFP fusion sample before Ni column. 
Lanes 2-9: mKATE-eGFP fusion elution from various minutes (min) throughout the 
gradient elution. Lane 10: molecular weight ladder. 
 
 
a 1:10 dilution of thrombin (stock concentration of 50 untils/µL) was added to the Fusion 
sample and a digest was performed over 15 hours. A second Ni column was run to 
separate the Fusion from the his6-tag and thrombin. This protein also showed impurities 
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fractions were collected from the ion exchange column, they were checked for purity via 
SDS-PAGE. As seen in Figure 12, fusion was successfully purified and samples of 




Figure 12. SDS-PAGE confirming mKATE2-eGFP fusion (53.25 kDa) purity after ion 
exchange chromatography. Lane 1: molecular weight ladder. Lane 2: mKATE2-eGFP 
fusion before ion exchange chromatography. Lanes 3-12: mKATE2-eGFP fusion elution 
from various minutes (min) throughout the gradient elution.  
 
 
2.4 Determination of Cellular HS1-monoHis Concentration 
An important aspect of creating a robust in vivo sensor is to ensure its presence 
does not perturb the natural biology of the analyte that is being monitored. In order to 
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different methods were employed to determine the ease and accuracy of each method. 
Both methods included creating a calibration curve with purified HS1-monoHis protein 
and testing the sensor concentrations of HS1-monoHis expressed on three different 
promoters. From weakest to strongest, the following promoters were tested via both 
methods: ADH1, TEF, and GPD. The first method was to gather cell lysates of these 
constructs, along with an empty vector (EV) control, and perform an immunoblot with 
equal protein loading to monitor expression and to deduce sensor concentrations for each 
promoter using the calibration curve of known, purified HS1-monoHis. The second 
method was to use cells in a plate reader to read in vivo fluorescence values, as well as to 
read the fluorescence of purified HS1-monoHis in various concentrations to create a 
calibration curve. While the latter method was much easier to accomplish, the 
immunoblotting gave a much smaller sensor concentration – giving a range of sensor 
concentrations between 1.39 nM and 28.1 nM for the three different promoters. The 
fluorescence method produced concentrations between 3.60 µM and 29.4 µM, about 1000 
times more concentrated than found by immunoblot. The fluorescence method operates 
under the assumption that the sensor behaves the same in vivo, like the different 
promoters in yeast cells, as it does in vitro, like the pure HS1-monoHis standards. Due to 
the smaller concentrations of the immunoblotting method, it was concluded that 
immunoblotting should be used in future tests of cellular sensor levels.  
 
2.4.1 Fluorescence Method 
In order to perform the fluorescence experiment, yeast cells were grown in 
Synthetic Complete-Leu (SC-Leu) medium. The following day, 10 OD/mL of cells were 
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collected, washed with water, and resuspended in 400 µL Phosphate-buffered saline 
(PBS). At this point, 100 µL of each construct was loaded into wells on a black-bottom 
fluoroplate alongside purified HS1-monoHis. The fluorescence of these cells was 
measured for both eGFP (excitation:480 nm, emission:510 nm) and mKATE2 
(excitation:580 nm, emission:620 nm). The concentrations of HS1-monoHis calculated 
from this experiment can be seen in Table 1. 
 
2.4.2 Immunoblotting Method 
In order to perform the immunoblot, yeast cells were lysed using zirconium oxide 
beads and a bullet blender. Lysate (20 µg) was then loaded onto a 12% tris tricine gel 
along with four standard concentrations of purified HS1-monoHis (C1-C4) to create a 
calibration curve. Once the gel was run, it was transferred onto a nitrocellulose 
membrane and blotted with α-GFP antibody to quantify the amount of HS1-monoHis 
present in each sample. As seen in Figure 13, the bands increase in intensity between the 
different promoters according to their increase in expression strength. After 
quantification of the bands, the concentrations of HS1-monoHis for each sample 
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Figure 13. Immunoblot analysis to monitor HS1-monoHis levels in yeast cells with 
different strength promoters. Samples were resolved on a 10% tris glycine gel, transferred 
to a nitrocellulose membrane, and detected with commercially available antibodies. Lane 
1: molecular weight marker. Lane 2: empty. Lanes 3-6: HS1-monoHis yeast cell lysates 
(20 µg) from increasing promoter strengths, EV, ADH1, TEF, and GPD. Lane 7: lysis 
buffer. Lane 8: empty. Lanes 9-12: purified HS1-monoHis in various concentrations to 
create a calibration curve. 
 
 
were calculated using the calibration curve. The summary of sensor concentrations can be 
seen in Table 1. The large difference in the sensor concentrations, which vary by a factor 
of 103, indicated that the immunoblotting method was the most sensitive and reliable 
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Table 1. HS1-monoHis concentrations calculated by immunoblotting and fluorescence 
Construct Western Blot (M) Plate Reader (M) 
ADH1 1.39x10-9 3.60x10-6 
TEF 1.15x10-8 1.44x10-5 
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CHAPTER 3 
IN CELL STUDIES OF VARIOUS HEME SENSORS 
 
3.1 Introduction 
To test the feasibility of these sensors in vivo, HS1, HS1-monoHis, and necessary 
controls were transformed into Saccharomyces cerevisiae, or Baker’s yeast. Yeast is an 
ideal model organism because of its relative ease to work with; its entire genome is 
sequenced and mapped, and it can easily be manipulated to grow with or without the 
production of heme35. The halting of the production of heme is accomplished by 
knocking out δ-aminolevulinic acid (ALA) synthase – the first enzyme in the biosynthetic 
pathway – giving the hem1Δ cell line36. This genetic mutation can be overcome upon 
addition of exogenous ALA, the next intermediate in the heme biosynthetic pathway. 
Yeast cells in both wild type (WT) and hem1Δ cells were transformed with the various 
heme sensors. 
 
3.2 Fluorescence Test of HS1 and Controls 
 Once all sensor mutants were transformed into both WT and hem1Δ cell lines, 
they were tested for the fluorescence of both chromophores. The first set of controls to be 
tested was eGFP, mKATE2, and the mKATE2-eGFP fusion. These controls were created 
to monitor the potential binding and quenching effects of heme to the chromophores 
without the presence of a strong heme-binding motif, like cyt b562. To this end, cells were 
grown in SC-Leu medium were treated with ergosterol and Tween-80 to support growth 
for hem1Δ cells (SCE-Leu medium). Hem1Δ cells have difficulty growing due to their 
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lack of ability to synthesize heme, which is vital in aerobic growth36. There was also a set 
of hem1Δ cells that were grown with ALA supplementation at a concentration to support 
WT levels of intracellular heme. This set of cells served as a control to show the ability of 
cells to be rescued with ALA and to account for any peripheral effects on fluorescence 
from knocking out ALA synthase when compared to WT cells.  
The following mutants in hem1Δ cells were grown in SCE-Leu medium and half 
were supplemented with 200 ng/µL ALA: HS1, eGFP, mKATE2, mKATE2-eGFP 
fusion, and EV. The following day, 5 OD600/mL of yeast cells were collected for each 
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Figure 14. Fluorescence ratio in response to the presence of heme. HS1 and mKATE-
eGFP fusion in hem1Δ yeast cells were inoculated without ALA (-ALA, blue bars) or 
supplemented with 200 ng/µL ALA (+ALA, red bars). After 15 hours of growth cells 
were added to a black-bottom fluoroplate and the eGFP fluorescence (excitation: 480 nm, 
emission: 510 nm) and mKATE fluorescence (excitation: 580 nm, emission: 620 nm) 
were measured. The ratio of eGFP:mKATE2 fluorescence was taken and is depicted 
above. An increase in heme concentration resulted in a decrease in eGFP fluorescence, 
resulting in a decrease in fluorescence ratio. The mKATE2-eGFP fusion was shown not 
to respond to heme because of its lack of heme-binding domain.  
 
 
of these cells was then read by the plate reader after adding 100 µL of cells to each well 
in a black-bottom fluoroplate. As seen in Figure 14, the fluorescence ratios of the two 
chromophore-containing sensor constructs responded differently to the presence of heme. 
Due to the ability of eGFP to have energy transfer with heme, we would expect the 
fluorescence ratio to decrease in HS1 upon heme binding. The fusion control, mKATE2-
eGFP, should not be affected by the presence of heme because of its lack of a heme-
binding region. As seen in Figure 14, there was quenching of eGFP fluorescence, thereby 
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also be seen that the Fusion control was insensitive to the presence of heme, confirming 
the need for cyt b562 to facilitate FRET. It can thus be concluded that our HS1 sensor has 
a specific response to heme binding due to the presence of cyt b562 and not due to a 
peripheral binding event to one or both of the chromophores.  
To extrapolate heme concentrations from fluorescence readouts, we need to know 
what value the fluorescence ratio of a 0% bound heme sensor looks like, as well as a 
100% bound sensor fluorescence ratio. This can be achieved via an in situ calibration of 
the sensors. This procedure was optimized using a detergent, digitonin, which 
permeabilized the plasma membrane to allow extracellular heme into the cells to saturate 
the sensor-binding motif, giving a fluorescence reading corresponding to 100% bound37.  
The same cells tested in Figure 14 were pelleted and resuspended in 400 µL of a 
PBS solution with 50 µg/mL digitonin. These cells were incubated at 30 °C for 30 
minutes to maximize permeabilization of the cell membranes. The PBS-digitonin solution 
was then removed, the cells were resuspended in 400 µL PBS, and the fluorescence was 
measured following the same conditions as the initial reading. One key difference from 
the initial fluorescence protocol above was the addition of a +/- heme condition to fully 
saturate the sensor after permeabilization. To the black-bottom fluoroplate 1 µL hemin 
chloride (1 mg/mL) solution was added to half of the wells to create the +heme condition. 
The other half of the plate was left without heme to give the –heme condition. As seen in 
Figure 15, HS1 was fully quenched upon heme addition following permeabilization. The 
HS1 fluorescence ratio shows a negative value for the +ALA+heme sample because it 
was quenched to below cellular background fluorescence. The blue bar for HS1 shows 
the ratio for what should be a 0% bound sensor due to its lack of ALA and heme, while  
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Figure 15. In situ calibration of HS1 and Fusion control. HS1 and mKATE-eGFP fusion 
in hem1Δ yeast cells were inoculated without ALA (-ALA) or supplemented with 200 
ng/µL ALA (+ALA). After 15 hours of growth cells were permeabilized with 50 µg/mL 
digitonin for 30 minutes and added to a black-bottom fluoroplate both with 1 mg/mL 
heme (+Heme) and without heme (-Heme) and the eGFP fluorescence (excitation: 480 
nm, emission: 510 nm) and mKATE fluorescence (excitation: 580 nm, emission: 620 nm) 
were measured. The ratio of eGFP:mKATE2 fluorescence was taken and is depicted 
above. An increase in heme concentration resulted in a decrease in eGFP fluorescence, 
resulting in a decrease in fluorescence ratio. The mKATE2-eGFP fusion was shown not 
to respond to heme because of its lack of heme-binding domain. 
 
 
the purple bar shows the ratio for 100% bound. It should also be noted that the mKATE2- 
eGFP fusion sensor was relatively unperturbed by the addition of ALA and heme. This 
yet again supports that the heme-binding domain is the only contributor to FRET 
exchange between heme and eGFP. This test was successful in laying the groundwork to 
show that HS1 responds uniquely to heme, as well as to optimize digitonin 
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A screen of sensor fluorescence was also performed with HS1, HS1-monoHis, 
and EV yeast cells to see the in vivo response of HS1-monoHis to heme compared to that 
of HS1. The three different sensor variants in yeast cells were inoculated for both WT 
and hem1Δ into SCE-Leu medium. The hem1Δ mutants were both supplemented with 
200 ng/µL ALA for heme production, as well as without ALA to give a zero heme 
background. After allowing them to grow overnight, cells were collected and 
resuspended in 1 mL PBS and the initial fluorescence was read for each of these 
constructs. Figure 16 shows the response of each sensor to the presence of ALA-
supported heme and no heme. As seen in Figure 16, +ALA HS1 is essentially entirely 
quenched, further confirming the need for a weaker-binding sensor to expand our 
dynamic range. HS1-monoHis shows that weaker-binding property by having a +ALA 
fluorescence ratio of 6.1, compared to that of essentially 0 for HS1. This screen shows 
proof of principle for the use of these sensors in vivo, as well as the benefits of creating a 
larger library of mutants to give different heme binding affinities.  
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Figure 16. Fluorescence ratios of HS1 and HS1-monoHis in hem1Δ yeast cells. HS1 and 
HS1-monoHis in hem1Δ yeast cells were inoculated without ALA (-ALA, blue bars) or 
supplemented with 200 ng/µL ALA (+ALA, red bars). After 15 hours of growth cells 
were added to a black-bottom fluoroplate and the eGFP fluorescence (excitation: 480 nm, 
emission: 510 nm) and mKATE fluorescence (excitation: 580 nm, emission: 620 nm) 
were measured. The ratio of eGFP:mKATE2 fluorescence was taken and is depicted 
above. An increase in heme concentration resulted in a decrease in eGFP fluorescence, 
resulting in a decrease in fluorescence ratio. HS1-monoHis was shown to have a weaker 
binding affinity for heme when compared to HS1. 
 
 
3.3 Heme Availability as a Function of Growth Phase 
Now that we have demonstrated the utility of HS1 and HS1-monoHis, we are 
poised to address different questions using our sensors. The first question addressed was 
whether heme availability changes as a function of growth phase. In yeast cells there are 
three different growth phases that can be related to their optical density: the lag phase, the 
exponential phase, and stationary phase. In the experiments done previously, cells were 
collected between the exponential and stationary phase, not diligently keeping growth 
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indicative of heme availability, was dependent on growth phase. To this end, both WT 
and hem1Δ cells harboring HS1, HS1-monoHis, and EV were inoculated into SCE-Leu 
medium and fluorescence was monitored for the early exponential phase (OD600 = 1) and 




Figure 17. Heme availability as a factor of growth phase. HS1 and HS1-monoHis in WT 
and hem1Δ (supplemented with 200 ng/ µL ALA)yeast cells were inoculated. After 15 
hours (exponential, blue bars) and 24 hours (stationary, red bars) of growth, cells were 
added to a black-bottom fluoroplate and the eGFP fluorescence (excitation: 480 nm, 
emission: 510 nm) and mKATE fluorescence (excitation: 580 nm, emission: 620 nm) 
were measured. The ratio of eGFP:mKATE2 fluorescence was taken and is depicted 
above. An increase in heme concentration resulted in a decrease in eGFP fluorescence, 
resulting in a decrease in fluorescence ratio.  
 
 
The bars in Figure 17 do not show a reliable increase in cytosolic heme 

































	   	   	  36	  
result can be clarified better through repeating the experiment and taking more times 
points. For example, it would be nice to take samples from a variety of growth stages 
ranging from the lag phase (OD600 = 0.5) to the stationary phase (OD600 = 5), including 
more steps throughout the exponential phase, eg (OD600 = 1, 3, 5, 7). It has now been 
shown that our HS1 sensors can be used to determine different effects of heme in yeast 
cells.  
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CHAPTER 4 
CONCLUSION AND FUTURE WORK 
 
4.1 Conclusion 
Heme is an important cofactor across various aspects of biology. Despite its 
ubiquitous nature in biology, relatively little is known about how heme is trafficked 
throughout the cell. To begin to understand this, a FRET-based heme sensor, HS1, was 
designed, purified, and expressed in vivo. HS1 was shown to be fully saturated with heme 
binding to cyt b562 in WT cells, so a different variant, HS1-monoHis, was created to have 
a weaker heme binding motif. This mutant was demonstrated to be less saturated with 
heme than HS1 in WT, but not devoid of heme as seen in the –ALA hem1Δ variant 
(Figure 16). In order to understand the concentration of our sensor as related to the pool 
of heme we’re sensing, the concentrations of sensor in three different promoters were 
measured and were found to need further testing.  
The sensors were expressed in vivo to show that they respond differently to 
different levels of heme upon ALA supplementation. As seen in the test of fluorescence 
as a result of growth phase, the sensors were able to detect different concentrations of 
heme available as a result of changing cellular environments. Our sensors have been 
validated to efficiently track heme changes in the cytosol and are now poised to answer 
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4.2 Future Work 
 Continued efforts are needed to expand the heme sensor library to create mutants 
that can cover a wider range of binding affinities, as well as design sensors that can 
selectively bind different oxidation states of heme. It would also be beneficial to create 
sensors that can be targeted to organelles known to require heme for their function, like 
the mitochondria and nucleus. This would allow the monitoring of heme movement to or 
from the cytosol in response to a stimulus, further uncovering the roles of heme in cell 
biology.  
 We would also benefit from the sensors being transfected into various mammalian 
cell lines representative of a number of diseases. Once a healthy cell line is reliably 
monitored, it would be helpful to compare the differences in heme availability in healthy 
cells to diseased cells. This can also be coupled to a genetic screen to elucidate the genes 
involved in regulating heme availability. These next steps are a few in a long line of 
necessary experiments needed to fully understand how heme functions throughout 
biology.   




Table 2. Description of plasmids used 
Plasmids Used Description 
pET30a(+) Bacterial expression plasmid with N-
terminal his6-tag 
pRH008 CG6 with his6-tag at the N-terminus and 
TEV cleavage site 
pRH013 HS1 with his6-tag at the N-terminus and 
TEV cleavage site 
pAR1023 HS1-monoHis with his6-tag at the N-
terminus and TEV cleavage site 
pRH001 CG6 with his6-tag at the N-terminus and 
thrombin cleavage site 
pRH002 eGFP with his6-tag at the N-terminus and 
thrombin cleavage site 
pRH007 mKATE2-eGFP fusion with his6-tag at the 
N-terminus and thrombin cleavage site 
 
 
Table 3. Primers used for PCR reactions 
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Expression and Purification of HS1. The gene encoding CG6 was digested with BamHI 
and HindIII, ligated into pET30a(+) to give pRH008, and confirmed by sequence 
analysis. The gene encoding mKATE2 was then digested with BamHI, ligated into 
pRH008 to give pRH013, and confirmed by sequence analysis. Escherichia coli 
BL21(DE3) containing pRH013 was incubated at 37 °C overnight in 20 mL Luria-
Bertani medium supplemented with 50 µg/mL kanamycin. The next morning, 20 mL of 
the overnight culture was used to inoculate 1 L of Luria-Bertani medium supplemented 
with 50 µg/mL kanamycin. The resulting cultures were grown at 20 °C to an OD600 = 0.8 
when protein expression was induced with the addition of 100 mM isopropyl β-D-
thiogalactopyranoside (IPTG). Cultures were incubated at 20 °C for an additional 45 h. 
Harvested cells were resuspended in 30 mL of lysis buffer (20 mM Tris, 100 mM NaCl, 
pH 8.0, 1 mM PMSF, 1X ProteaseArrest™, 0.1X DNase). The cell membrane was 
disturbed using a French Pressure Cell Press (two passes on high at 1200 psi, 4 °C). The 
lysate was clarified by centrifugation (20000 rpm, 4 °C, 30 min). Total protein 
concentration was determined by the method of Bradford, using bovine serum albumin as 
a standard38. The cell-free extract was then loaded onto a 20 mL HisPrep FF 16/10 
column prepacked with pre-charged Ni sepharose (GE Healthcare) with equilibration 
buffer (20 mM Tris, 100 mM NaCl, pH 8.0, 20 mM imidazole) to baseline as measured 
by UV-Vis. The HS1 protein was eluted by a gradient of 0 to 100% elution buffer (20 
mM Tris, 100 mM NaCl, pH 8.0, 300 mM imidazole) over 15 column volumes, or 300 
mL, collecting 10 mL fractions. Fractions containing the protein as confirmed via SDS-
PAGE analysis were pooled and dialyzed against 3 L TEV cleavage buffer (20 mM Tris, 
100 mM NaCl, pH 8.0) at 4 °C. The following day the his6-tag was cleaved by adding a 
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1:1 molar ratio of TEV:HS1 and letting it incubate at room temperature for 18 h. 
Following incubation, the protein was loaded onto a 1 mL HisTrap HP column prepacked 
with pre-charged Ni sepharose (GE Healthcare) with equilibration buffer at 0.1 mL/min. 
Once all of the protein was loaded, the protein was eluted by increasing the flow rate to 1 
mL/min, collecting 1 mL fractions. Upon elution, purity was checked via SDS-PAGE and 
was found to need further purification. The fractions containing HS1 were pooled and 
loaded onto a HiTrap Q HP 1 mL anion exchange column (GE Healthcare) with 
equilibration buffer (20 mM Tris, 10 mM NaCl, pH 8.0) at 0.1 mL/min. The column was 
washed with 5 column volumes of equilibration buffer at 1 mL/min and then equilibrated 
with 10% elution buffer (20 mM Tris, 1 M NaCl, pH 8.0). The protein was then eluted 
with a gradient of 10 to 25% elution buffer over 30 column volumes, or 30 mL, at a flow 
rate of 1 mL/min, collecting 300 µL fractions. Once purity was confirmed via SDS-
PAGE, fractions were stored at 4 °C. 
 
Expression and Purification of HS1-monoHis. The Met7 residue in cyt b562 was 
changed to Ala7 by a Quick Change polymerase chain reaction (PCR) using primers 
prRH008 and prRH008-r to give pAR1023. The product was confirmed by sequence 
analysis. Escherichia coli BL21(DE3) containing pAR1023 was incubated at 37 °C 
overnight in 20 mL Luria-Bertani medium supplemented with 50 µg/mL kanamycin. The 
next morning, 20 mL of the overnight culture was used to inoculate 1 L of Luria-Bertani 
medium supplemented with 50 µg/mL kanamycin. The resulting cultures were grown at 
20 °C to an OD600 = 0.8 when protein expression was induced with the addition of 100 
mM isopropyl β-D-thiogalactopyranoside (IPTG). Cultures were incubated at 20 °C for 
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an additional 45 h. Harvested cells were resuspended in 30 mL of lysis buffer (20 mM 
Tris, 100 mM NaCl, pH 8.0, 1 mM PMSF, 1X ProteaseArrest™, 0.1X DNase). The cell 
membrane was disturbed using a French Pressure Cell Press (two passes on high at 1200 
psi, 4 °C). The lysate was clarified by centrifugation (20000 rpm, 4 °C, 30 min). Total 
protein concentration was determined by the method of Bradford, using bovine serum 
albumin as a standard38. The cell-free extract was then loaded onto a 20 mL HisPrep FF 
16/10 column prepacked with pre-charged Ni sepharose (GE Healthcare) with 
equilibration buffer (20 mM Tris, 100 mM NaCl, pH 8.0, 20 mM imidazole) to baseline 
as measured by UV-Vis. The HS1-monoHis protein was eluted by gradient of 0 to 100% 
elution buffer (20 mM Tris, 100 mM NaCl, pH 8.0, 300 mM imidazole) over 15 column 
volumes, or 300 mL, collecting 10 mL fractions. Fractions containing the protein as 
confirmed via SDS-PAGE were pooled and dialyzed against 3 L TEV cleavage buffer 
(20 mM Tris, 100 mM NaCl, pH 8.0). The following day the his6-tag was cleaved by 
adding a 1:1 molar ratio of TEV:HS1-monoHis and letting it incubate at room 
temperature for 18 h. Following incubation, the protein was loaded onto a 1 mL HisTrap 
HP column prepacked with pre-charged Ni sepharose (GE Healthcare) with equilibration 
buffer at 0.1 mL/min. Once all of the protein was loaded, the protein was eluted by 
increasing the flow rate to 1 mL/min, collecting 1 mL fractions. Upon elution, purity was 
checked via SDS-PAGE and was found to need further purification. The fractions 
containing HS1-monoHis were pooled and loaded onto a HiTrap Q HP 1 mL cation 
exchange column (GE Healthcare) with equilibration buffer (20 mM Tris, 10 mM NaCl, 
pH 8.0) at 0.1 mL/min. The column was washed with 5 column volumes of equilibration 
buffer at 1 mL/min and then equilibrated with 10% elution buffer (20 mM Tris, 1 M 
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NaCl, pH 8.0). The protein was then eluted with a gradient of 10 to 25% elution buffer 
over 30 column volumes, or 30 mL, at a flow rate of 1 mL/min, collecting 300 µL 
fractions. Once purity was confirmed via SDS-PAGE analysis, fractions were stored at    
4 °C. 
 
Expression and Purification of mKATE2-eGFP Fusion. The gene encoding cyt b562 
was amplified out of the CG6 in pRH001 through two rounds of polymerase chain 
reaction (PCR) using primers prRC004, prRC005, prRC006, and prRC007. The product, 
pRH002, was confirmed by sequence analysis. The gene encoding mKATE2 was then 
digested with BamHI, ligated into pRH002 to give pRH007, and confirmed by sequence 
analysis. Escherichia coli BL21(DE3) containing pRH007 was incubated at 37 °C 
overnight in 20 mL Luria-Bertani medium supplemented with 50 µg/mL kanamycin. The 
next morning, 20 mL of the overnight culture was used to inoculate 1 L of Luria-Bertani 
medium supplemented with 50 µg/mL kanamycin. The resulting cultures were grown at 
25 °C to an OD600 = 0.8 when protein expression was induced with the addition of 100 
mM isopropyl β-D-thiogalactopyranoside (IPTG). Cultures were incubated at 25 °C for 
an additional 24 h. Harvested cells were resuspended in 30 mL of lysis buffer (20 mM 
Tris, 100 mM NaCl, pH 8.0, 1 mM PMSF, 1X ProteaseArrest™, 0.1X DNase). The cell 
membrane was disturbed using a French Pressure Cell Press (two passes on high at 1200 
psi, 4 °C). The lysate was clarified by centrifugation (20000 rpm, 4 °C, 30 min). Total 
protein concentration was determined by the method of Bradford, using bovine serum 
albumin as a standard38. The cell-free extract was then loaded onto a 20 mL HisPrep FF 
16/10 column prepacked with pre-charged Ni sepharose (GE Healthcare) with 
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equilibration buffer (20 mM Tris, 100 mM NaCl, pH 8.0, 20 mM imidazole) to baseline 
as measured by UV-Vis. The Fusion protein was eluted by gradient of 0 to 100% elution 
buffer (20 mM Tris, 100 mM NaCl, pH 8.0, 300 mM imidazole) over 15 column 
volumes, or 300 mL, collecting 10 mL fractions. Fractions containing the protein as 
confirmed via SDS-PAGE were pooled and dialyzed against 3 L cleavage buffer (20 mM 
Tris, 100 mM NaCl, pH 8.0) to remove imidazole. The following day the his6-tag was 
cleaved by adding a 1:10 dilution of thrombin (stock at a concentration of 50 units/µL) 
and letting it incubate at room temperature for 15 h. Following incubation, the protein 
was loaded onto a 1 mL HisTrap HP column prepacked with pre-charged Ni sepharose 
(GE Healthcare) with equilibration buffer at 0.1 mL/min. Once all of the protein was 
loaded, the protein was eluted by increasing the flow rate to 1 mL/min, collecting 1 mL 
fractions. Upon elution, purity was checked via SDS-PAGE and was found to need 
further purification. The fractions containing the Fusion were pooled and loaded onto a 
HiTrap Q HP 1 mL anion exchange column (GE Healthcare) with equilibration buffer 
(20 mM Tris, 10 mM NaCl, pH 8.0) at 0.1 mL/min. The column was washed with 5 
column volumes of equilibration buffer at 1 mL/min and then equilibrated with 10% 
elution buffer (20 mM Tris, 1 M NaCl, pH 8.0). The protein was then eluted with a 
gradient of 10 to 25% elution buffer over 30 column volumes, or 30 mL, at a flow rate of 
1 mL/min, collecting 300 µL fractions. Once purity was confirmed via SDS-PAGE, 
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